These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

859 related items for PubMed ID: 19476423

  • 1. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
    Miller LJ.
    Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
    [Abstract] [Full Text] [Related]

  • 2. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
    Baptista T, Kin NM, Beaulieu S, de Baptista EA.
    Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
    [Abstract] [Full Text] [Related]

  • 3. Role of metformin for weight management in patients without type 2 diabetes.
    Desilets AR, Dhakal-Karki S, Dunican KC.
    Ann Pharmacother; 2008 Jun; 42(6):817-26. PubMed ID: 18477733
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of metformin for prevention of weight gain in psychiatric populations: a review.
    Newall H, Myles N, Ward PB, Samaras K, Shiers D, Curtis J.
    Int Clin Psychopharmacol; 2012 Mar; 27(2):69-75. PubMed ID: 21979790
    [Abstract] [Full Text] [Related]

  • 5. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents.
    Arman S, Sadramely MR, Nadi M, Koleini N.
    Saudi Med J; 2008 Aug; 29(8):1130-4. PubMed ID: 18690305
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.
    Ellinger LK, Ipema HJ, Stachnik JM.
    Ann Pharmacother; 2010 Apr; 44(4):668-79. PubMed ID: 20233913
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The effect of metformin on anthropometrics and insulin resistance in patients receiving atypical antipsychotic agents: a meta-analysis.
    Ehret M, Goethe J, Lanosa M, Coleman CI.
    J Clin Psychiatry; 2010 Oct; 71(10):1286-92. PubMed ID: 20441727
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.
    Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL.
    J Clin Psychiatry; 2001 Oct; 62 Suppl 23():45-66. PubMed ID: 11603885
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM, Mignon L, Meyer JM.
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.